Michael Gilman

Michael Gilman was the founder of Stromedix, Inc. (founded 2006), where the title held was Chief Executive Officer in 2012.
Dr. Gilman was the founder of X4 Pharmaceuticals, Inc. (founded 2014), holding the title of Director.
Dr. Gilman is the founder of Padlock Therapeutics, Inc. (founded 2014), serving as President, Director & Secretary since 2014.
Dr. Gilman was the founder of Obsidian Therapeutics, Inc. (founded 2015), where the title held was Chief Executive Officer & Director from 2015 to 2019.
Current jobs include Chairman at Arrakis Therapeutics, Inc. since 2016, Director at Scholar Rock, Inc. since 2013, Independent Director at Scholar Rock Holding Corp.
since 2013, and Scientific Advisor at FutuRx Ltd. Former jobs include Director at EPIX Pharmaceuticals, Inc., Director at Via Science, Inc., Chief Scientific Officer & Executive VP at ARIAD Pharmaceuticals, Inc. from 1994 to 1999, Senior Vice President-Early-Stage Pipeline at Biogen, Inc. from 2012 to 2013, and Executive Vice President-Research at Biogen, Inc. from 1999 to 2005.
Education includes an undergraduate degree from Massachusetts Institute of Technology conferred in 1976 and a doctorate from the University of California, Berkeley conferred in 1983.